Gedatolisib

N/A

Report date: 2026/05/20 20:02:01
NMEFirst In Class

Base Information

Drug NameGedatolisib
Drug Alias Name吉托利司gedatolisib吉达利塞gedatolisibumGedatolisb +[9] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPI3-kinase class I inhibitorsSerine/threonine-protein kinase mTOR inhibitors
TargetsPI3-kinase class ISerine/threonine-protein kinase mTOR
Therapy Area/IndicationsSolid tumoursUrologic DiseasesProstatic Diseases +[19] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[29] 
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaN/A
Originator CompaniesWyeth Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesCelcuity IncPfizer Inc
Inactive CompaniesDana-Farber Cancer InstituteInstitut CurieCristiana Sessa +[4] 
Active IndicationsUrologic DiseasesProstatic DiseasesGenital Diseases, Male +[8] 
Inactive IndicationsSolid tumoursEndometrial NeoplasmsSmall Cell Lung Carcinoma +[11] 

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG